We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+25.81%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$241M
AUM Growth
+$50.3M
Cap. Flow
+$11.8M
Cap. Flow %
4.88%
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17

Top Buys

Rank Stock Value
1
BEPC icon
Brookfield Renewable
BEPC
+$1.51M
2
WES icon
Western Midstream Partners
WES
+$926K
3
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
+$707K
4
DK icon
Delek US
DK
+$681K
5
CVI icon
CVR Energy
CVI
+$669K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.61M
2
AIMT
Aimmune Therapeutics
AIMT
+$1.13M
3
AIV
Aimco
AIV
+$1.1M
4
VIV icon
Telefônica Brasil
VIV
+$1.01M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$988K

Sector Composition

Rank Sector Weight
1 Healthcare 29.53%
2 Real Estate 18.96%
3 Energy 16.61%
4 Materials 11.31%
5 Utilities 7.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
276
DELISTED
Molecular Templates, Inc.
MTEM
$270K 0.11%
1,915
+463
+32% +$68.4K
ALBO
277
DELISTED
Albireo Pharma Inc
ALBO
$270K 0.11%
+7,192
New +$262K
APLT
278
DELISTED
Applied Therapeutics
APLT
$269K 0.11%
12,216
+4,645
+61% +$96.7K
ASND icon
279
Ascendis Pharma A/S
ASND
$16.5B
$269K 0.11%
1,614
-601
-27% -$99.4K
LITS
280
Lite Strategy Inc
LITS
$32.4M
$269K 0.11%
5,095
+679
+15% +$39.2K
RVMD icon
281
Revolution Medicines
RVMD
$38.5B
$269K 0.11%
6,805
-1,733
-20% -$68.5K
PRVB
282
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$269K 0.11%
15,878
-5,607
-26% -$84K
SRNE
283
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$269K 0.11%
39,387
-27,464
-41% -$221K
CNST
284
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$269K 0.11%
9,331
+391
+4% +$9.84K
KNSA icon
285
Kiniksa Pharmaceuticals
KNSA
$6.31B
$268K 0.11%
15,148
+831
+6% +$14.6K
TCDA
286
DELISTED
Tricida, Inc. Common Stock
TCDA
$267K 0.11%
37,919
+25,838
+214% +$198K
ALLO icon
287
Allogene Therapeutics
ALLO
$625M
$266K 0.11%
10,536
+2,925
+38% +$95.3K
AKRO
288
DELISTED
Akero Therapeutics
AKRO
$265K 0.11%
10,276
-2,410
-19% -$67K
EFR
289
Eaton Vance Senior Floating-Rate Fund
EFR
$314M
$265K 0.11%
20,802
-4,644
-18% -$58.1K
KROS icon
290
Keros Therapeutics
KROS
$197M
$265K 0.11%
+3,758
New +$237K
ATNX
291
DELISTED
Athenex, Inc. Common Stock
ATNX
$265K 0.11%
1,200
-55
-4% -$13.5K
ANAB icon
292
AnaptysBio
ANAB
$1.54B
$263K 0.11%
12,251
-4,381
-26% -$106K
DRNA
293
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$263K 0.11%
11,939
-3,425
-22% -$75.4K
IMGN
294
DELISTED
Immunogen Inc
IMGN
$262K 0.11%
40,635
-29,578
-42% -$173K
CRDF icon
295
Cardiff Oncology
CRDF
$63M
$261K 0.11%
+14,533
New +$255K
NKTX icon
296
Nkarta
NKTX
$152M
$261K 0.11%
+4,239
New +$176K
NXTC icon
297
NextCure
NXTC
$20.4M
$261K 0.11%
1,999
+917
+85% +$118K
AKBA icon
298
Akebia Therapeutics
AKBA
$338M
$260K 0.11%
92,771
+65,225
+237% +$190K
BCRX icon
299
BioCryst Pharmaceuticals
BCRX
$2.42B
$259K 0.11%
34,707
-37,137
-52% -$191K
SNDX icon
300
Syndax Pharmaceuticals
SNDX
$1.7B
$259K 0.11%
11,624
-8,270
-42% -$172K
10 11
12
13 14

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2020 Portfolio in Review

As of Q4 2020, Virtus ETF Advisers held 372 positions worth $241M, up 26% from $191M the previous quarter. Its ten largest holdings account for 9.4% of the portfolio.

Virtus ETF Advisers deployed $11.8M of net new capital in Q4 2020, opening 47 new positions and adding to 146 existing holdings. Its largest new stake was Harmony Biosciences: 14,899 shares worth $539K.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $572K trimmed.

  • Virtus ETF Advisers's largest Q4 2020 buy was Harmony Biosciences: 14,899 shares worth $539K.
  • Virtus ETF Advisers added most to Brookfield Renewable in Q4 2020, an estimated $1.51M increase.
  • Virtus ETF Advisers's biggest Q4 2020 reduction was Amicus Therapeutics, cutting an estimated $572K.
  • Virtus ETF Advisers fully exited Immunomedics Inc in Q4 2020, selling an estimated $1.61M.
  • Virtus ETF Advisers's ten largest holdings make up 9.4% of its $241M portfolio in Q4 2020.
  • Virtus ETF Advisers opened 47 new positions and closed 17 in Q4 2020.
  • Virtus ETF Advisers's portfolio value rose 26% quarter-over-quarter to $241M.

Based on Virtus ETF Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.